Trial reportRespiratory research2018
A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.
Trial report in Respiratory research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Impacts of Environmental Pollutants on Innate Immunity: The Role of Group 2 Innate Lymphoid Cells.Clinical reviews in allergy & immunology · 2026Review
- Advances in DNAzyme Selection, Molecular Engineering and Biomedical Applications.International journal of molecular sciences · 2026Review
- Studies on the Effect of Lipofectamine and Cell-Penetrating Peptide on the Properties of 10-23 DNAzyme.Molecules (Basel, Switzerland) · 2023Article
- A computational approach to identify efficient RNA cleaving 10-23 DNAzymes.NAR genomics and bioinformatics · 2023Article
- A promising nucleic acid therapy drug: DNAzymes and its delivery system.Frontiers in molecular biosciences · 2023Review
- A modular XNAzyme cleaves long, structured RNAs under physiological conditions and enables allele-specific gene silencing.Nature chemistry · 2022Article
- Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.Cellular and molecular neurobiology · 2022Review
- Perspectives in Therapy of Chronic Rhinosinusitis.Diagnostics (Basel, Switzerland) · 2022Review
- The Combined Value of Type2 Inflammatory Markers in Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2022Article
- RNA-cleaving DNAzymes as a diagnostic and therapeutic agent against antimicrobial resistant bacteria.Current genetics · 2022Review
- Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer.International journal of biological sciences · 2022Article
- Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI.Scandinavian journal of immunology · 2021Review
- Review
- Granulocyte-targeted therapies for airway diseases.Pharmacological research · 2020Review
- Site-specific functionalization with amino, guanidinium, and imidazolyl groups enabling the activation of 10-23 DNAzyme.RSC advances · 2020Article
- Future Trends in Nebulized Therapies for Pulmonary Disease.Journal of personalized medicine · 2020Review
- Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundA subset of COPD-patients presents with eosinophilic airway inflammation. While treatment of asthmatic patients with the GATA3-specific DNAzyme SB010 attenuated sputum eosinophilia after allergen challenge, this specific treatment has not been evaluated in patients with COPD. Our objective was to evaluate the feasibility and safety of inhaled SB010 in COPD patients with sputum eosinophilia.
methodsWe conducted a randomized, double-blind, placebo-controlled, multicentre clinical trial in COPD-patients with sputum eosinophilia (≥2.5% non-squamous cells). Patients inhaled 10 mg SB010 bid or matching placebo via the controlled inhalation system AKITA2 APIXNEB for 28 days. Endpoints included the feasibility of the study (primary), patient's safety, sputum eosinophils, F
resultsOne hundred thirty patients were screened, 23 patients were randomized (FEV
conclusionIn patients with eosinophilic COPD, sputum eosinophils could be reduced by inhalation of SB010. Long-term studies are needed to demonstrate clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.